NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Recruiting · Phase 2 · NCT06821997
Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma
At a glance
- Research payments reported, 2025
- $29,890
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Roswell Park Cancer Institute
- Tested
- Biospecimen Collection (procedure), Computed Tomography (procedure), Fluorouracil (drug), Irinotecan Sucrosofate (drug), Leucovorin Calcium (drug), Oxaliplatin (drug), Surgical Procedure (procedure)
- Dates
- Started 2026-03-02; completion 2027-03-01
- Results posted
- Not yet
This phase II trial tests how well liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) before surgery works in treating patients with pancreatic ductal adenocarcinoma that is close to major blood vessels, but is still potentially removable by surgery (borderline resectable). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Liposomal irinotecan is a form of the anticancer drug irinotecan that is contained inside very tiny, fat-like particles. Liposomal irinotecan may have fewer side effects and work better tha…
From ClinicalTrials.gov, last updated 2026-09-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $29,890 in research payments for this study in 2025 (1 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Roswell PArk Comprehensive Cancer Center $29,890
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.